Paper28596308
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
Le DT and 45 others. Science, 2017. Cited by 5,477 papers, by iCite.
Cite this record
ConductScience Library. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Papers, record 28596308. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28596308
- Disease
- colorectal cancer741 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Clinical Trial, Phase II, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- PubMed
Connected records4
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Diseases4
- colorectal cancerOne of its trials lists the paper741 drugs, 2,239 trials
- malignant colon neoplasmOne of its trials lists the paper144 drugs, 220 trials
- colon carcinomaOne of its trials lists the paper132 drugs, 195 trials
- intrahepatic cholangiocarcinomaOne of its trials lists the paper84 drugs, 157 trials
Topics20
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibodies, Monoclonal, Humanized | Major topic |
| Biomarkers, Tumor | Major topic |
| Brain Neoplasms | Major topic |
| Colorectal Neoplasms | Major topic |
| Neoplastic Syndromes, Hereditary | Major topic |
| Programmed Cell Death 1 Receptor | Major topic |
| Adult | |
| Aged | |
| Aged, 80 and over | |
| Antigens, Neoplasm | |
| Cell Cycle Checkpoints | |
| DNA Mismatch Repair | |
| Disease-Free Survival | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Mutation | |
| T-Lymphocytes | |
| Young Adult |
Source PubMed
Grants17
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| U01 CA067941 | NCI NIH HHS | United States | R01CA067941 | PubMed and NIH | NIH RePORTER |
| T32 GM007309 | NIGMS NIH HHS | United States | T32GM007309 | PubMed and NIH | NIH RePORTER |
| K12 CA090625 | NCI NIH HHS | United States | K12CA090625 | PubMed | NIH RePORTER |
| Howard Hughes Medical Institute | United States | PubMed | PubMed | ||
| P50 CA098252 | NCI NIH HHS | United States | P50CA098252 | PubMed and NIH | NIH RePORTER |
| R01 CA203891 | NCI NIH HHS | United States | R01CA203891 | PubMed and NIH | NIH RePORTER |
| R37 CA057345 | NCI NIH HHS | United States | R01CA057345 | PubMed and NIH | NIH RePORTER |
| P30 CA016058 | NCI NIH HHS | United States | P30CA016058 | PubMed and NIH | NIH RePORTER |
| R01 CA057345 | NCI NIH HHS | United States | R01CA057345 | PubMed and NIH | NIH RePORTER |
| K23 CA163672 | NCI NIH HHS | United States | K23CA163672 | PubMed and NIH | NIH RePORTER |
| R01 CA067941 | NCI NIH HHS | United States | R01CA067941 | PubMed and NIH | NIH RePORTER |
| R37 CA043460 | NCI NIH HHS | United States | R37CA043460 | PubMed and NIH | NIH RePORTER |
| P50 CA062924 | NCI NIH HHS | United States | P50CA062924 | PubMed and NIH | NIH RePORTER |
| P30 CA006973 | NCI NIH HHS | United States | P30CA006973 | PubMed and NIH | NIH RePORTER |
| R37CA057345 | NIH | NIH RePORTER | |||
| U01CA067941 | NIH | NIH RePORTER | |||
| ZIABC011343 | NIH | NIH RePORTER |
Trials19
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT01876511 | Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors (Cohorts A, B and C) | Background | ClinicalTrials.gov | |
| NCT03832621 | NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Microsatellite Stable, MGMT Silenced Metastatic Colorectal Cancer | Background | ClinicalTrials.gov | |
| NCT03895970 | Lenvatinib Combined Pembrolizumab in Advanced Hepatobiliary Tumors | Background | ClinicalTrials.gov | |
| NCT04197219 | Pembrolizumab With Axitinib in Recurrent Endometrial Cancer | Background | ClinicalTrials.gov | |
| NCT04622423 | Advanced Therapies for Liver Metastases | Background | ClinicalTrials.gov | |
| NCT04866862 | Fruquitinib Combined With Camrelizumab in Non MSI-H/dMMR Refractory Colorectal Cancer | Results | ClinicalTrials.gov | |
| NCT05097599 | StrataPATH™ (Precision Indications for Approved Therapies) | Background | ClinicalTrials.gov | |
| NCT05119829 | Melanoma: Genomic Profiles, Molecular Markers and Therapeutic Implications | Background | ClinicalTrials.gov | |
| NCT05854030 | Serum Exosomal miRNA Predicting the Therapeutic Efficiency in Lung Squamous Carcinoma | Results | ClinicalTrials.gov | |
| NCT05933980 | Toripalimab,Celecoxib and Regorafenib in the Treatment of Refractory Advanced Colorectal Cancer | Background | ClinicalTrials.gov | |
| NCT06004713 | Registry Study in MSI/dMMR Solid Tumors | Background | ClinicalTrials.gov | |
| NCT06098560 | Circulating Tumor DNA (ctDNA) as a Predictive Biomarker for Immunotherapy in Advanced or Locally Advanced dMMR/MSI-H Colorectal Patients | Background | ClinicalTrials.gov | |
| NCT06370663 | First-line Treatment for Unresectable Locally Advanced Distal Cholangiocarcinoma Combining Radiotherapy and HAIC | Results | ClinicalTrials.gov | |
| NCT06709885 | HDAC Inhibitor Combination With Chemoimmunotherapy in the Neoadjuvant Treatment of pMMR Locally Advanced Colon Cancer | Results | ClinicalTrials.gov | |
| NCT07550088 | BAL/BOT/agenT-797 in pMMR CRC With Liver Metastases | Background | ClinicalTrials.gov | |
| NCT07622667 | Correlation Analysis of Gene Characteristics of Malignant Tumors With Prognosis | Background | ClinicalTrials.gov | |
| NCT07841236 | ctDNA-Guided Immunotherapy for dMMR/MSI-H Colon Cancer | Background | ClinicalTrials.gov | |
| NCT07845565 | FMT Plus SHR-1701 With Nab-Paclitaxel/Gemcitabine as First-Line Treatment for Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma | Background | ClinicalTrials.gov | |
| NCT07854977 | Fecal Microbiota Transplantation Combined With NALIRIFOX Plus Serplulimab as First-line Treatment for Advanced or Metastatic Pancreatic Ductal Adenocarcinoma. | Background | ClinicalTrials.gov |
Comments and corrections3
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment in | 28619894 | In a major shift, cancer drugs go 'tissue-agnostic'. | https://conductscience.org/library/papers/28619894 | PubMed |
| Comment in | 28751597 | Genetic biomarker for cancer immunotherapy. | https://conductscience.org/library/papers/28751597 | PubMed |
| Comment in | 28811675 | Biomarkers: Matching mutations to immunotherapy response. | https://conductscience.org/library/papers/28811675 | PubMed |
References32
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 25428504 | Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. | Nature | 2014 | https://conductscience.org/library/papers/25428504 | PubMed |
| 2 | 25858804 | Immune checkpoint blockade: a common denominator approach to cancer therapy. | Cancer Cell | 2015 | https://conductscience.org/library/papers/25858804 | PubMed |
| 3 | 23177514 | Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. | Lancet | 2013 | https://conductscience.org/library/papers/23177514 | PubMed |
| 4 | 10362805 | High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability. | Am J Pathol | 1999 | https://conductscience.org/library/papers/10362805 | PubMed |
| 5 | 28031159 | Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. | Cancer Discov | 2017 | https://conductscience.org/library/papers/28031159 | PubMed |
| 6 | 25897158 | Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. | J Clin Oncol | 2015 | https://conductscience.org/library/papers/25897158 | PubMed |
| 7 | 25800770 | Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. | J Clin Oncol | 2015 | https://conductscience.org/library/papers/25800770 | PubMed |
| 8 | 25428505 | PD-1 blockade induces responses by inhibiting adaptive immune resistance. | Nature | 2014 | https://conductscience.org/library/papers/25428505 | PubMed |
| 9 | 27694933 | Classification and characterization of microsatellite instability across 18 cancer types. | Nat Med | 2016 | https://conductscience.org/library/papers/27694933 | PubMed |
| 10 | 25765070 | Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. | Science | 2015 | https://conductscience.org/library/papers/25765070 | PubMed |
| 11 | 8030745 | Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. | Am J Pathol | 1994 | https://conductscience.org/library/papers/8030745 | PubMed |
| 12 | 25877891 | Personalized genomic analyses for cancer mutation discovery and interpretation. | Sci Transl Med | 2015 | https://conductscience.org/library/papers/25877891 | PubMed |
| 13 | 16825502 | Comparison of the microsatellite instability analysis system and the Bethesda panel for the determination of microsatellite instability in colorectal cancers. | J Mol Diagn | 2006 | https://conductscience.org/library/papers/16825502 | PubMed |
| 14 | 19934295 | Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. | Clin Cancer Res | 2009 | https://conductscience.org/library/papers/19934295 | PubMed |
| 15 | 28129544 | Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. | Cell | 2017 | https://conductscience.org/library/papers/28129544 | PubMed |
| 16 | 25358689 | The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. | Cancer Discov | 2015 | https://conductscience.org/library/papers/25358689 | PubMed |
| 17 | 15528789 | Development of a fluorescent multiplex assay for detection of MSI-High tumors. | Dis Markers | 2004 | https://conductscience.org/library/papers/15528789 | PubMed |
| 18 | 18245491 | Epitope landscape in breast and colorectal cancer. | Cancer Res | 2008 | https://conductscience.org/library/papers/18245491 | PubMed |
| 19 | 9872311 | Genetic instabilities in human cancers. | Nature | 1998 | https://conductscience.org/library/papers/9872311 | PubMed |
| 20 | 24157944 | Using synthetic templates to design an unbiased multiplex PCR assay. | Nat Commun | 2013 | https://conductscience.org/library/papers/24157944 | PubMed |
Cited by4,039
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5,477 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42984928 | Immunotherapy in Advanced Epithelial Ovarian Cancer: Successes and Frustrations. | Oncol Res | 2026 | https://conductscience.org/library/papers/42984928 | PubMed |
| 42983056 | A patient with Lynch syndrome and duodenal neuroendocrine carcinoma achieved a pathologic complete response to immune checkpoint inhibitor therapy selected based on comprehensive genomic profiling. | Virchows Arch | 2026 | https://conductscience.org/library/papers/42983056 | PubMed |
| 42973860 | Context-dependent cGAS-STING signaling in solid tumors: biological determinants, clinical implications, and biomarker-guided therapeutic strategies. | Front Immunol | 2026 | https://conductscience.org/library/papers/42973860 | PubMed |
| 42964829 | Non-invasive electromagnetic fields induce anti-tumor neutrophil reprogramming and enhance checkpoint blockade in breast cancer. | Front Immunol | 2026 | https://conductscience.org/library/papers/42964829 | PubMed |
| 42953524 | Advances in immunotherapy for gastrointestinal malignancies. | Front Immunol | 2026 | https://conductscience.org/library/papers/42953524 | PubMed |
| 42945895 | Characterising the genomic landscape of two clinical risk groups in CD30+ T-cell lymphoproliferative disorders with cutaneous involvement: a multi-institutional retrospective study. | EBioMedicine | 2026 | https://conductscience.org/library/papers/42945895 | PubMed |
| 42943387 | Precision Microbiome Interventions in Oncology: From Predictive Biomarkers to Therapeutic Modulation of Immunotherapy Outcomes. | Microorganisms | 2026 | https://conductscience.org/library/papers/42943387 | PubMed |
| 42941537 | Prediction of Pathological Complete Response to Neoadjuvant Immunotherapy-Based Regimens for Non-Metastatic Colon and Rectal Cancer. | J Clin Med | 2026 | https://conductscience.org/library/papers/42941537 | PubMed |
| 42941329 | Molecular Profiles, Treatment-Associated Survival, and Prognosis in Early-Onset Versus Late-Onset Gastric Cancer: A Systematic Review and Meta-Analysis. | J Clin Med | 2026 | https://conductscience.org/library/papers/42941329 | PubMed |
| 42936277 | WRN helicase addiction in MSI-H colorectal cancer: biomarker-guided pharmacology, resistance evolution, and implications for other gastrointestinal cancers. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42936277 | PubMed |
| 42928874 | Nanotechnology-Enabled Immunotherapy for Colorectal Cancer: Overcoming the "Cold" Tumor Microenvironment in Microsatellite-Stable Disease. | Int J Nanomedicine | 2026 | https://conductscience.org/library/papers/42928874 | PubMed |
| 42923368 | Induced mismatch repair deficiency: a hypothesis for the transient and reversible sensitization of mismatch repair-proficient tumors to Immune checkpoint blockade. | Front Immunol | 2026 | https://conductscience.org/library/papers/42923368 | PubMed |
| 42920873 | Unexpected favorable response of stage IV gastric adenocarcinoma to sintilimab combined with chemotherapy: A case report. | Oncol Lett | 2026 | https://conductscience.org/library/papers/42920873 | PubMed |
| 42910256 | Metabolic Barriers to Cancer Immunotherapy: Multiscale Mechanisms from Organelle Dysfunction to Organ-Specific Constraints. | Int J Biol Sci | 2026 | https://conductscience.org/library/papers/42910256 | PubMed |
| 42901717 | PCSK9 drives acquired resistance to anti-PD-1 immunotherapy through cystine metabolic reprogramming in lung cancer. | J Immunother Cancer | 2026 | https://conductscience.org/library/papers/42901717 | PubMed |
| 42897348 | Molecular predictors of minimal residual disease in newly diagnosed multiple myeloma treated with quadruplet therapy. | Nat Med | 2026 | https://conductscience.org/library/papers/42897348 | PubMed |
| 42892624 | Single-cell RNA sequencing identifies a proinflammatory S100a8/a9+ macrophage subset contributing to acute kidney injury. | Inflamm Res | 2026 | https://conductscience.org/library/papers/42892624 | PubMed |
| 42882903 | Intensive Care in Patients with Solid Tumours: A Practical Framework for Integrated Onco-Critical Care. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42882903 | PubMed |
| 42879043 | Resistance Phenotypes and Treatment Sequencing After Immune Checkpoint Blockade in MSI-H/dMMR Metastatic Colorectal Cancer: A Review. | J Gastrointest Cancer | 2026 | https://conductscience.org/library/papers/42879043 | PubMed |
| 42870820 | Exploratory study to evaluate the combined effect of CBM588: Clostridium butyricum in platinum plus pemetrexed with pembrolizumab for non-small cell lung cancer-protocol of MIYABRO study. | Transl Lung Cancer Res | 2026 | https://conductscience.org/library/papers/42870820 | PubMed |
Genes14
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Drugs6
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets | Source |
|---|---|---|---|---|---|
| CAPECITABINE | CHEMBL1773 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL1773 | ChEMBL |
| TUCIDINOSTAT | CHEMBL3621988 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL3621988 | ChEMBL |
| CAMRELIZUMAB | CHEMBL4297715 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL4297715 | ChEMBL |
| TISLELIZUMAB | CHEMBL4297840 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL4297840 | ChEMBL |
| FRUQUINTINIB | CHEMBL4303214 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL4303214 | ChEMBL |
| GEMCITABINE | CHEMBL888 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL888 | ChEMBL |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/28596308
GET https://conductscience.org/api/papers/v1/28596308/authors?page=2